Clear Cell Carcinoma: Clinical Trials

4 trials for Clear Cell Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed, 1 recruiting. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 2, Completed 1, Recruiting 1

Follow Clear Cell Carcinoma: new trials by email Literature Review of Clear Cell Carcinoma trials Research Report on Clear Cell Carcinoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy - Ovarian Cancer, Fallopian Tube Cancer
Phase 2RecruitingNorth Eastern German Society of Gynaecological Oncology6402024-10-112026-10-23
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Dostarlimab, Bevacizumab, Doxorubicin - Ovarian Neoplasms, Endometrial Neoplasms
Phase 2Active not recruitingYonsei University1982024-01-222026-11-02
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
vudalimab - Ovarian Cancer, Clear Cell Carcinoma
Phase 2Active not recruitingXencor, Inc.1702022-07-212025-02-07
A Study of Nivolumab in Selected Uterine Cancer Patients
Nivolumab - Uterine Cancer, Endometrial Carcinoma
Phase 2CompletedMemorial Sloan Kettering Cancer Center352017-08-032024-12-27

Narrower conditions

Adenocarcinoma, Clear Cell (4)  ·  Endometrial Neoplasms (3)  ·  Ovarian Neoplasms (3)  ·  Fallopian Tube Neoplasms (2)  ·  Uterine Cervical Neoplasms (2)  ·  Carcinosarcoma (1)  ·  Leiomyosarcoma (1)  ·  Prostatic Neoplasms (1)  ·  Uterine Neoplasms (1)  ·  Vaginal Neoplasms (1)  ·  Vulvar Neoplasms (1)

Broader conditions

Adenocarcinoma (4)  ·  Carcinoma (4)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Genital Diseases (4)  ·  Genital Diseases, Female (4)  ·  Genital Neoplasms, Female (4)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms by Site (4)  ·  Neoplasms, Glandular and Epithelial (4)  ·  Urogenital Diseases (4)  ·  Urogenital Neoplasms (4)  ·  Adnexal Diseases (3)  ·  Endocrine Gland Neoplasms (3)

Interventions

Bevacizumab (1)  ·  Doxorubicin (1)  ·  Gemcitabine (1)  ·  Nivolumab (1)  ·  Paclitaxel (1)  ·  dostarlimab (1)  ·  liposomal doxorubicin (1)

Sponsors

Memorial Sloan Kettering Cancer Center (1)  ·  North Eastern German Society of Gynaecological Oncology (1)  ·  Xencor, Inc. (1)  ·  Yonsei University (1)

Countries

United States (2)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Japan (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Claire Friedman, MD (1)  ·  Jalid Sehouli, Prof. Dr. med. (1)  ·  Jolene Shorr (1)

Results publications

PMID 38653864, PMID 39710508, PMID 39990653, PMID 42140839